Rigaku Corporation, part of Rigaku Holdings Corporation, is teaming up with SPERA PHARMA, Inc. announced a new partnership. This collaboration will speed up innovation in drug development. The partnership combines the advanced tech and expertise of both companies. This aims to create transformative solutions in the industry.
SPERA PHARMA will use Rigaku’s XtaLAB Synergy-ED in its analytical services. This platform is a top-notch integrated electron diffraction tool. This integration will help SPERA PHARMA support clients better in drug development.
The XtaLAB Synergy-ED system uses 3D ED/MicroED technology. It helps analyze structures of substances like tiny crystals and small amounts of crystalline powder. This ability should improve the accuracy and speed of drug research and development.
